ESSA Pharma Inc. announced the presentation of updated dose escalation data from its Phase 1/2 study at the European Society of Medical Oncology 2023 Congress.
AI Assistant
ESSA PHARMA INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.